Aesica unveils a new High Capacity Manufacturing Facility investing £30 million at its Queenborough, UK site

Aesica unveils a new High Capacity Manufacturing Facility investing £30 million at its Queenborough, UK site  

New facility specifically built to produce a solid dose medication for   treating Type 2 diabetes in adults

 19 September 2013: Aesica, the global contract development and manufacturing organisation (CDMO), has today announced the creation of a new High Capacity Manufacturing Facility following a £30 million investment at its Queenborough, Kent site. The 10,000 sq. m expansion has been constructed for the production of a solid dose medication used in treating one of the world's most common lifestyle diseases: Type 2 diabetes in adults.

Following today's official opening, commercial production at the facility will commence in November. The facility contains a large amount of highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system.

Her Majesty's Lord- Lieutenant of Kent, Viscount De L'Isle attended the ceremony to unveil the opening of the new facility, doing so in recognition of the contribution that Aesica is making to the regional economy, both in terms of the creation of new jobs and commercial expansion.

Aesica Pharmaceuticals is well established as a manufacturer and a major exporter of formulated products with this latest investment reflecting the continued growth in export demand experienced by the company. This specific product manufactured at the new facility has global sales and is set for worldwide export.     

Aesica is already a strong, committed, local employer in the Queenborough area and with this latest investment and expansion, the facility will have a dedicated workforce of 55 technicians who will be recruited locally and trained on site. The design of the facility will allow the current capacity to be more than doubled in the future which would require a further additional 50 staff to be recruited.

Dr Robert Hardy, CEO of Aesica Pharmaceuticals commented: "The new investment and opening of the High Capacity Manufacturing Facility marks another key milestone for our company and a further step towards achieving our vision to be the world's number one supplier of APIs and formulated products to the pharmaceutical industry."

He continued: "The formulation of the solid dose product for the treatment of Type 2 diabetes is a perfect example of the type of high quality and high healthcare demand drugs that we manufacture for supply to the international market place."     



About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

About Aesica:

·         Aesica is one of the UK's most innovative and versatile drug contract development and manufacturing companies.

·         Aesica services its customers across the full product lifecycle from development to commercial supply and formulated products represents 75% of the company's business.

·         As a young company celebrating its 10th anniversary in 2014, Aesica has achieved great success supporting many of the world's top 20 pharmaceutical companies with six European facilities and a 1,300-strong international workforce.

·         Aesica develops long-term strategic partnerships with its clients to help them deliver value into the market place.

·         Silvefleet Capital, the European private equity firm, invested in the business in 2011.

For media enquiries, please contact Alex Heeley or Tristan Jervis at De Facto Communications on: +44 (0) 20 7203 6740 or e-mail; [email protected].      


Tristan Jervis

Managing Partner


Description: DF logo

Holborn Gate, 26 Southampton Buildings

London WC2A 1BP


Telephone: +44 (0)207 203 6742

Direct: +44 (0)207 203 6740

E-mail: [email protected]